Nuformix PLC Director/PDMR Shareholding (9789X)
January 10 2022 - 11:23AM
UK Regulatory
TIDMNFX
RNS Number : 9789X
Nuformix PLC
10 January 2022
10 January 2022
Nuformix plc
("Nuformix" or the "the Company")
Director/PDMR Shareholding
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that today the Company received notice that
Dr Alastair Riddell purchased 400,000 ordinary shares of 0.1 pence
each ("Ordinary Shares") at a price of 1.175 pence per share on 10
January 2022.
- Ends -
Nuformix plc via Walbrook
Dr Alastair Riddell, Executive
Chairman
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44
(0)20 7933 8780
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 /
+44 (0)7867 984 082
Enquiries:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Alastair Riddell
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status PDMR - Executive Chairman
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Nuformix plc
---------------------------- -------------------------------------
b) LEI 2138003XG3H3I2J3BJ24
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of nominal value
financial instrument, 0.1 pence each
type of instrument
Identification code GB00BYW79Y38
---------------------------- -------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1.175p 400,000
----------
---------------------------- -------------------------------------
d) Aggregated information
- Aggregated volume 400,000
- Price 1.175p
- Total GBP4,700.00
---------------------------- -------------------------------------
e) Date of the transaction 10 January 2022
---------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, Main Market
---------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHGPUUPGUPPGQU
(END) Dow Jones Newswires
January 10, 2022 11:23 ET (16:23 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024